Jiangzhong Pharmaceutical Co Ltd (600750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-2.91 Million ≈ $-425.37K USD) by net assets (CN¥4.70 Billion ≈ $688.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangzhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jiangzhong Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Jiangzhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangzhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Optics Technology Holding Co Ltd
SHE:300489
|
-0.012x |
|
Compania Cervecerias Unidas SA
SN:CCU
|
-0.020x |
|
Shenzhen Hymson Laser Intelligent Equipments Co Ltd
SHG:688559
|
0.058x |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
0.138x |
|
Zillow Group Inc
NASDAQ:ZG
|
0.015x |
|
Dentsply Sirona Inc
NASDAQ:XRAY
|
0.053x |
|
Elekta AB (publ)
ST:EKTA-B
|
0.075x |
|
VIVENDI UNSPON.ARD EO 55
F:VVUD
|
N/A |
Annual Cash Flow Conversion Efficiency for Jiangzhong Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Jiangzhong Pharmaceutical Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Jiangzhong Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.70 Billion ≈ $688.21 Million |
CN¥970.87 Million ≈ $142.07 Million |
0.206x | +17.40% |
| 2024-12-31 | CN¥4.47 Billion ≈ $654.34 Million |
CN¥786.25 Million ≈ $115.05 Million |
0.176x | -21.44% |
| 2023-12-31 | CN¥4.63 Billion ≈ $677.30 Million |
CN¥1.04 Billion ≈ $151.58 Million |
0.224x | -1.26% |
| 2022-12-31 | CN¥4.51 Billion ≈ $659.65 Million |
CN¥1.02 Billion ≈ $149.51 Million |
0.227x | +13.26% |
| 2021-12-31 | CN¥4.58 Billion ≈ $670.56 Million |
CN¥917.04 Million ≈ $134.19 Million |
0.200x | +13.06% |
| 2020-12-31 | CN¥4.25 Billion ≈ $622.10 Million |
CN¥752.50 Million ≈ $110.11 Million |
0.177x | +8.34% |
| 2019-12-31 | CN¥3.92 Billion ≈ $574.26 Million |
CN¥641.18 Million ≈ $93.82 Million |
0.163x | +9.32% |
| 2018-12-31 | CN¥3.25 Billion ≈ $476.08 Million |
CN¥486.25 Million ≈ $71.15 Million |
0.149x | +248.77% |
| 2017-12-31 | CN¥2.92 Billion ≈ $426.61 Million |
CN¥124.93 Million ≈ $18.28 Million |
0.043x | -83.94% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.77 Million |
CN¥698.05 Million ≈ $102.15 Million |
0.267x | +23.02% |
| 2015-12-31 | CN¥2.35 Billion ≈ $344.55 Million |
CN¥510.78 Million ≈ $74.74 Million |
0.217x | +29.69% |
| 2014-12-31 | CN¥2.13 Billion ≈ $312.15 Million |
CN¥356.80 Million ≈ $52.21 Million |
0.167x | +218.82% |
| 2013-12-31 | CN¥2.13 Billion ≈ $312.16 Million |
CN¥111.92 Million ≈ $16.38 Million |
0.052x | -52.42% |
| 2012-12-31 | CN¥2.05 Billion ≈ $300.43 Million |
CN¥226.38 Million ≈ $33.13 Million |
0.110x | +25.64% |
| 2011-12-31 | CN¥1.92 Billion ≈ $280.62 Million |
CN¥168.30 Million ≈ $24.63 Million |
0.088x | -29.76% |
| 2010-12-31 | CN¥1.78 Billion ≈ $260.34 Million |
CN¥222.29 Million ≈ $32.53 Million |
0.125x | -64.56% |
| 2009-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
CN¥378.32 Million ≈ $55.36 Million |
0.353x | +27.13% |
| 2008-12-31 | CN¥969.41 Million ≈ $141.86 Million |
CN¥268.87 Million ≈ $39.34 Million |
0.277x | +51.28% |
| 2007-12-31 | CN¥837.97 Million ≈ $122.62 Million |
CN¥153.63 Million ≈ $22.48 Million |
0.183x | +148.45% |
| 2006-12-31 | CN¥748.62 Million ≈ $109.55 Million |
CN¥55.24 Million ≈ $8.08 Million |
0.074x | -73.89% |
| 2005-12-31 | CN¥702.13 Million ≈ $102.74 Million |
CN¥198.45 Million ≈ $29.04 Million |
0.283x | +612.79% |
| 2004-12-31 | CN¥662.81 Million ≈ $96.99 Million |
CN¥26.28 Million ≈ $3.85 Million |
0.040x | -67.88% |
| 2003-12-31 | CN¥639.80 Million ≈ $93.62 Million |
CN¥78.98 Million ≈ $11.56 Million |
0.123x | -25.18% |
| 2002-12-31 | CN¥575.21 Million ≈ $84.17 Million |
CN¥94.90 Million ≈ $13.89 Million |
0.165x | +120.25% |
| 2001-12-31 | CN¥551.04 Million ≈ $80.63 Million |
CN¥41.28 Million ≈ $6.04 Million |
0.075x | -66.43% |
| 2000-12-31 | CN¥545.76 Million ≈ $79.86 Million |
CN¥121.77 Million ≈ $17.82 Million |
0.223x | +625.92% |
| 1999-12-31 | CN¥516.08 Million ≈ $75.52 Million |
CN¥-21.89 Million ≈ $-3.20 Million |
-0.042x | -3.26% |
| 1998-12-31 | CN¥277.86 Million ≈ $40.66 Million |
CN¥-11.42 Million ≈ $-1.67 Million |
-0.041x | -- |
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsu… Read more